1. 2033 Stage III colorectal cancer (CRC) in Spain: A retrospective analysis from 35 centres. (September 2015) Authors: Sotelo, L.; Sastre, J.; García-Paredes, B.; Cabezas-Camarero, S.; Vieitez, J.M.; Alonso, V.; Grávalos, C.; Escudero, P; Vera, R.; Aranda, E.; García-Alfonso, P.; Gallego-Plazas, J.; Lopez, C.; Pericay, C.; Arrivi, A.; Vicente, P; Ballesteros, P; Elez, E.; Lopez-Ladron, A.; Diaz-Rubio, E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2051 Relation between RAS mutations and radiologic (RECIST and morphologic) and pathologic response, in hepatic metastasis secondary to colorectal cancer: The AVAMET study. (September 2015) Authors: Garcia, R. Vera; Gomez, M.L.; Ayuso, J.R.; Figueras, J.; Alfonso, P Garcia; Martinez, V.; Lacasta, A.; Ruiz, A.; Safont, M.J.; Aparicio, J.; Campos, J.M.; Camara, J.C.; Martin-Richard, M.; Montagut, C.; Pericay, C.; Vieitez, J.M.; Falco, E.; Jorge, M.; Marin, M.; Salgado, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S345 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 2128 Early tumour shrinkage (ETS) and depth of response (DpR) with first-line panitumumab (P) plus FOLFOX4 (P-FOLFOX4) or FOLFIRI (P-FOLFIRI) in patients (pts) with wild-type (WT) RAS colorectal cancer (CRC) and liver-limited disease (LLD). (September 2015) Authors: Abad, A.; Massuti, B.; Gravalos, C.; Escudero, P; Guillen-Ponce, C.; Manzano, J.L.; Ortiz, M.J.; Safont, M.J.; Gallego, J.; Sastre, J.; Pericay, C.; Duenas, R.; Rivera, F.; Losa, F.; Valladares-Ayerbes, M.; Gonzalez, E.; Robles, L.; Aranda, E.; Carrato, A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S374 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 2161 The prognostic significance of radiologic and pathologic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-years update GEMCAD 0801 trial. (September 2015) Authors: Machado, I.; Patel, U.; Brown, G.; Salud, A.; Gil, M.; Montagut, C.; Busto, M.; Safont, M.; Maurel, J.; Ayuso, J.; Aparicio, J.; Feliu, J.; Vera, R.; Alonso, V.; Gallego, J.; Martin, M.; Pericay, C.; Ballesteros, E.; Santos, J.; Fernandez-Martos, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S387 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗